TMV has also been shown to be an excellent carrier for whole antigen vaccination against other viral disease antigens [52,53,54], so testing whole antigen fusions for LMP1, LMP2, and EBNA may be considered in the future. This evidence concerns the gene PSMB9 and viral infectious disease.